Clinical Study

Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma

Figure 3

Kaplan-Meier curves showed a lower rate of overall survival in HCC patients with high expression of serum SALL4 than with low expression of serum SALL4.
262385.fig.003